You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 147 No. 2, February 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Cancer-Associated Hypercalcemia With Cisplatin

Thomas E. Lad, MD; Howard M. Mishoulam, MD; Daniel H. Shevrin, MD; Lawrence J. Kukla, MD; Edith C. Abramson, MD; Subhash C. Kukreja, MD

Arch Intern Med. 1987;147(2):329-332.


Abstract

• Cisplatin (cis-platinum) has been shown to lower cancerassociated humoral hypercalcemia in an animal model and to inhibit bone resorption in vitro. This prospective study was designed to evaluate the efficacy of cisplatin in treating cancer-associated hypercalcemia in humans. Thirteen patients with severe hypercalcemia refractory to rehydration were treated with a 24-hour infusion of cisplatin, 100 mg/m2. Serial measurements of serum calcium and tumor size were made following cisplatin treatment and compared with pretreatment values. Nine patients (69%) achieved normocalcemia after treatment with cisplatin; and mean duration of benefit was 38 days in these patients. No reduction in tumor size was seen. All patients died of progressive cancer. We conclude that cisplatin can control malignant hypercalcemia for relatively long periods, and that its mechanism of action is not due to a reduction in tumor size.

(Arch Intern Med 1987;147:329-332)



Author Affiliations

From the Sections of Medical Oncology (Drs Lad, Mishoulam, Shevrin, and Kukla) and Endocrinology (Drs Abramson and Kukreja), Department of Medicine, West Side Veterans Administration and University of Illinois Hospitals, University of Illinois College of Medicine, Chicago.


Footnotes

Accepted for publication July 1, 1986.

Reprint requests to Medical Oncology Section (MP 111), Veterans Administration West Side Medical Center, PO Box 8195, Chicago, IL 60680 (Dr Lad).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Endocrine Effects of Nonhormonal Antineoplastic Therapy
Yeung et al.
Endocr. Rev. 1998;19:144-172.
ABSTRACT | FULL TEXT  

To the Editor.--
Heiselman
Arch Intern Med 1987;147:1361-1361.
ABSTRACT  

Hypercalcemia of Malignancy
Bennett
Arch Intern Med 1987;147:1357-1361.
ABSTRACT  

To the Editor.---Reply
Lad et al.
Arch Intern Med 1987;147:1361-1361.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.